Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jianxin Lin

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
Leukemia & Lymphoma|June 23, 2025
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of KEYNOTE-204 by prior lines of therapyJohn Kuruvilla, Dipenkumar Modi, Armando Santoro, et al.
Chest|May 28, 2026
Sotatercept Safety and Efficacy in Intermediate-Low Risk Pulmonary Arterial Hypertension: A Pooled Analysis of PULSAR and STELLARMardi Gomberg-Maitland, H Ardeschir Ghofrani, J Simon R Gibbs, et al.
JTO Clinical and Research Reports|September 30, 2021
Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042Aaron S Mansfield, Roy S Herbst, Gilberto de Castro, et al.
Blood|August 15, 2019
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087Robert Chen, Pier Luigi Zinzani, Hun Ju Lee, et al.
Immunotherapy|July 19, 2023
Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in AsiaYing Cheng, James Chih-Hsin Yang, Isamu Okamoto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2022
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 StudyGilberto de Castro, Iveta Kudaba, Yi-Long Wu, et al.
Cancer Research and Treatment|June 27, 2025
Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 StudySe Hoon Park, Yen-Hwa Chang, Jae Lyun Lee, et al.
Japanese Journal of Clinical Oncology|January 16, 2025
First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern AsiaHsiao-Jen Chung, Chihiro Kondoh, Woo Kyun Bae, et al.
Cell Metabolism|March 12, 2013
Class II major histocompatibility complex plays an essential role in obesity-induced adipose inflammationTuo Deng, Christopher J Lyon, Laurie J Minze, et al.
Blood|June 15, 2023
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphomaPhilippe Armand, Pier Luigi Zinzani, Hun Ju Lee, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Leukemia & Lymphoma|June 23, 2025
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of KEYNOTE-204 by prior lines of therapyJohn Kuruvilla, Dipenkumar Modi, Armando Santoro, et al.
Chest|May 28, 2026
Sotatercept Safety and Efficacy in Intermediate-Low Risk Pulmonary Arterial Hypertension: A Pooled Analysis of PULSAR and STELLARMardi Gomberg-Maitland, H Ardeschir Ghofrani, J Simon R Gibbs, et al.
JTO Clinical and Research Reports|September 30, 2021
Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042Aaron S Mansfield, Roy S Herbst, Gilberto de Castro, et al.
Blood|August 15, 2019
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087Robert Chen, Pier Luigi Zinzani, Hun Ju Lee, et al.
Immunotherapy|July 19, 2023
Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in AsiaYing Cheng, James Chih-Hsin Yang, Isamu Okamoto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2022
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 StudyGilberto de Castro, Iveta Kudaba, Yi-Long Wu, et al.
Cancer Research and Treatment|June 27, 2025
Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 StudySe Hoon Park, Yen-Hwa Chang, Jae Lyun Lee, et al.
Japanese Journal of Clinical Oncology|January 16, 2025
First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern AsiaHsiao-Jen Chung, Chihiro Kondoh, Woo Kyun Bae, et al.
Cell Metabolism|March 12, 2013
Class II major histocompatibility complex plays an essential role in obesity-induced adipose inflammationTuo Deng, Christopher J Lyon, Laurie J Minze, et al.
Blood|June 15, 2023
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphomaPhilippe Armand, Pier Luigi Zinzani, Hun Ju Lee, et al.
Pageof 9